THE PAPWORTH PLUG – successful use of high dose fibrinogen concentrate and platelet concentrate in potential life-threatening complication after cardiopulmonary bypass surgery in a patient with Type 2M Vicenza von Willebrand Disease
Restricted accessResearch articleFirst published online July, 2012
THE PAPWORTH PLUG – successful use of high dose fibrinogen concentrate and platelet concentrate in potential life-threatening complication after cardiopulmonary bypass surgery in a patient with Type 2M Vicenza von Willebrand Disease
Anecdotally, fibrinogen concentrate (FC) has been used as a “universal” haemostatic agent in complex post-cardiopulmonary bypass (CPB) coagulopathy. We present a case where FC and two pools of platelets prevented life-threatening bleeding in a patient with moderate von Willebrand Disease (vWD) immediately post CPB.
SchneppenheimRFedericiABBuddeU. Von Willebrand Disease type 2M “Vicenza” in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. J Thromb Haemost2000; 83: 136–40.
2.
GadisseurAHermansCBernemanZSchroyensWDeckmynHMichielsJJ. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematologica2009; 121: 71–84.
3.
MichielsJJvan VlietHHBernemanZ. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease type 1, 2 and 3. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2007; 13: 14–34.
4.
Ltd. GU.SPC Alphanate. Cambridge: The electronic Medicines (eMC) Compendium, 2012, p. Summary of Product Characteristics.
5.
DanesAFCuencaLGBuenoSRMendarte BarrenecheaLRonsanoJB. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang2008; 94: 221–226.
6.
RothnieNGKinmonthJB. Bleeding after perfusion for open heart surgery. Importance of unneutralized heparin and its proper correction. Br Med J1960; 1: 73–78.
7.
TeohKHYoungEBlackallMHRobertsRSHirshJ. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?J Thorac Cardiovasc Surg2004; 128: 211–219.
BesserMWKleinAA. The coagulopathy of cardiopulmonary bypass. Critical reviews in clinical laboratory sciences2010; 47: 197–212.
10.
KarlssonMTernstromLHyllnerM. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost2009; 102: 137–144.
11.
SorensenBBevanD. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol2010Jun; 149(6): 834-843. Epub 2010 Apr 29.
12.
Rahe-MeyerNPichlmaierMHaverichA. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth2009; 102: 785–792.
13.
ChandlerWLVelanT. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood2003; 101: 4355–4362.
14.
MorrisonGAChalmersRTSolomonCNimmoAF. Fibrinogen concentrate therapy guided by thromboelastometry as an alternative to fresh frozen plasma in major vascular surgery. J Cardiothorac Vasc Anaesth2011September27, Epub ahead of print.
15.
SolomonCCadamuroJZieglerB. A comparison of fibrinogen measurement methods with fibrin clot elasticity assessed by thromboelastometry, before and after administration of fibrinogen concentrate in cardiac surgery patients. Transfusion2011; 51: 1695–1706.
16.
BolligerDSzlamFMolinaroRJRahe-MeyerNLevyJHTanakaKA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth2009; 102: 793–799.
